Src family kinases differentially influence glioma growth and motility

Laura J. Lewis-Tuffin, Ryan Feathers, Priya Hari, Nisha Durand, Zhimin Li, Fausto J. Rodriguez, Katie Bakken, Brett Carlson, Mark Schroeder, Jann N Sarkaria, Panagiotis Z Anastasiadis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Src-family kinase (SFK) signaling impacts multiple tumor-related properties, particularly in the context of the brain tumor glioblastoma. Consequently, the pan-SFK inhibitor dasatinib has emerged as a therapeutic strategy, despite physiologic limitations to its effectiveness in the brain. We investigated the importance of individual SFKs (Src, Fyn, Yes, and Lyn) to glioma tumor biology by knocking down individual SFK expression both in culture (LN229, SF767, GBM8) and orthotopic xenograft (GBM8) contexts. We evaluated the effects of these knockdowns on tumor cell proliferation, migration, and motility-related signaling in culture, as well as overall survival in the orthotopic xenograft model. The four SFKs differed significantly in their importance to these properties. In culture, Src, Fyn, and Yes knockdown generally reduced growth and migration and altered motility-related phosphorylation patterns while Lyn knockdown did so to a lesser extent. However the details of these effects varied significantly depending on the cell line: in no case were conclusions about the role of a particular SFK applicable to all of the measures or all of the cell types examined. In the orthotopic xenograft model, mice implanted with non-target or Src or Fyn knockdown cells showed no differences in survival. In contrast, mice implanted with Yes knockdown cells had longer survival, associated with reduced tumor cell proliferation. Those implanted with Lyn knockdown cells had shorter survival, associated with higher overall tumor burden. Together, our results suggest that Yes signaling directly affects tumor cell biology in a pro-tumorigenic manner, while Lyn signaling affects interactions between tumor cells and the microenvironment in an anti-tumor manner. In the context of therapeutic targeting of SFKs, these results suggest that pan-SFK inhibitors may not produce the intended therapeutic benefit when Lyn is present.

Original languageEnglish (US)
Pages (from-to)1783-1798
Number of pages16
JournalMolecular Oncology
Volume9
Issue number9
DOIs
StatePublished - Nov 1 2015

Fingerprint

src-Family Kinases
Glioma
Growth
Heterografts
Neoplasms
Cell Movement
Cell Proliferation
Cellular Microenvironment
Tumor Microenvironment
Glioblastoma
Tumor Burden
Brain Neoplasms
Cell Biology
Therapeutics
Phosphorylation
Cell Line
Brain

Keywords

  • Dasatinib
  • Glioblastoma
  • Lyn kinase
  • Migration
  • Proliferation
  • Src-family kinase

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Lewis-Tuffin, L. J., Feathers, R., Hari, P., Durand, N., Li, Z., Rodriguez, F. J., ... Anastasiadis, P. Z. (2015). Src family kinases differentially influence glioma growth and motility. Molecular Oncology, 9(9), 1783-1798. https://doi.org/10.1016/j.molonc.2015.06.001

Src family kinases differentially influence glioma growth and motility. / Lewis-Tuffin, Laura J.; Feathers, Ryan; Hari, Priya; Durand, Nisha; Li, Zhimin; Rodriguez, Fausto J.; Bakken, Katie; Carlson, Brett; Schroeder, Mark; Sarkaria, Jann N; Anastasiadis, Panagiotis Z.

In: Molecular Oncology, Vol. 9, No. 9, 01.11.2015, p. 1783-1798.

Research output: Contribution to journalArticle

Lewis-Tuffin, LJ, Feathers, R, Hari, P, Durand, N, Li, Z, Rodriguez, FJ, Bakken, K, Carlson, B, Schroeder, M, Sarkaria, JN & Anastasiadis, PZ 2015, 'Src family kinases differentially influence glioma growth and motility', Molecular Oncology, vol. 9, no. 9, pp. 1783-1798. https://doi.org/10.1016/j.molonc.2015.06.001
Lewis-Tuffin LJ, Feathers R, Hari P, Durand N, Li Z, Rodriguez FJ et al. Src family kinases differentially influence glioma growth and motility. Molecular Oncology. 2015 Nov 1;9(9):1783-1798. https://doi.org/10.1016/j.molonc.2015.06.001
Lewis-Tuffin, Laura J. ; Feathers, Ryan ; Hari, Priya ; Durand, Nisha ; Li, Zhimin ; Rodriguez, Fausto J. ; Bakken, Katie ; Carlson, Brett ; Schroeder, Mark ; Sarkaria, Jann N ; Anastasiadis, Panagiotis Z. / Src family kinases differentially influence glioma growth and motility. In: Molecular Oncology. 2015 ; Vol. 9, No. 9. pp. 1783-1798.
@article{9a1ad8d19c524edeaaf86f7abc5db461,
title = "Src family kinases differentially influence glioma growth and motility",
abstract = "Src-family kinase (SFK) signaling impacts multiple tumor-related properties, particularly in the context of the brain tumor glioblastoma. Consequently, the pan-SFK inhibitor dasatinib has emerged as a therapeutic strategy, despite physiologic limitations to its effectiveness in the brain. We investigated the importance of individual SFKs (Src, Fyn, Yes, and Lyn) to glioma tumor biology by knocking down individual SFK expression both in culture (LN229, SF767, GBM8) and orthotopic xenograft (GBM8) contexts. We evaluated the effects of these knockdowns on tumor cell proliferation, migration, and motility-related signaling in culture, as well as overall survival in the orthotopic xenograft model. The four SFKs differed significantly in their importance to these properties. In culture, Src, Fyn, and Yes knockdown generally reduced growth and migration and altered motility-related phosphorylation patterns while Lyn knockdown did so to a lesser extent. However the details of these effects varied significantly depending on the cell line: in no case were conclusions about the role of a particular SFK applicable to all of the measures or all of the cell types examined. In the orthotopic xenograft model, mice implanted with non-target or Src or Fyn knockdown cells showed no differences in survival. In contrast, mice implanted with Yes knockdown cells had longer survival, associated with reduced tumor cell proliferation. Those implanted with Lyn knockdown cells had shorter survival, associated with higher overall tumor burden. Together, our results suggest that Yes signaling directly affects tumor cell biology in a pro-tumorigenic manner, while Lyn signaling affects interactions between tumor cells and the microenvironment in an anti-tumor manner. In the context of therapeutic targeting of SFKs, these results suggest that pan-SFK inhibitors may not produce the intended therapeutic benefit when Lyn is present.",
keywords = "Dasatinib, Glioblastoma, Lyn kinase, Migration, Proliferation, Src-family kinase",
author = "Lewis-Tuffin, {Laura J.} and Ryan Feathers and Priya Hari and Nisha Durand and Zhimin Li and Rodriguez, {Fausto J.} and Katie Bakken and Brett Carlson and Mark Schroeder and Sarkaria, {Jann N} and Anastasiadis, {Panagiotis Z}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.molonc.2015.06.001",
language = "English (US)",
volume = "9",
pages = "1783--1798",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Src family kinases differentially influence glioma growth and motility

AU - Lewis-Tuffin, Laura J.

AU - Feathers, Ryan

AU - Hari, Priya

AU - Durand, Nisha

AU - Li, Zhimin

AU - Rodriguez, Fausto J.

AU - Bakken, Katie

AU - Carlson, Brett

AU - Schroeder, Mark

AU - Sarkaria, Jann N

AU - Anastasiadis, Panagiotis Z

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Src-family kinase (SFK) signaling impacts multiple tumor-related properties, particularly in the context of the brain tumor glioblastoma. Consequently, the pan-SFK inhibitor dasatinib has emerged as a therapeutic strategy, despite physiologic limitations to its effectiveness in the brain. We investigated the importance of individual SFKs (Src, Fyn, Yes, and Lyn) to glioma tumor biology by knocking down individual SFK expression both in culture (LN229, SF767, GBM8) and orthotopic xenograft (GBM8) contexts. We evaluated the effects of these knockdowns on tumor cell proliferation, migration, and motility-related signaling in culture, as well as overall survival in the orthotopic xenograft model. The four SFKs differed significantly in their importance to these properties. In culture, Src, Fyn, and Yes knockdown generally reduced growth and migration and altered motility-related phosphorylation patterns while Lyn knockdown did so to a lesser extent. However the details of these effects varied significantly depending on the cell line: in no case were conclusions about the role of a particular SFK applicable to all of the measures or all of the cell types examined. In the orthotopic xenograft model, mice implanted with non-target or Src or Fyn knockdown cells showed no differences in survival. In contrast, mice implanted with Yes knockdown cells had longer survival, associated with reduced tumor cell proliferation. Those implanted with Lyn knockdown cells had shorter survival, associated with higher overall tumor burden. Together, our results suggest that Yes signaling directly affects tumor cell biology in a pro-tumorigenic manner, while Lyn signaling affects interactions between tumor cells and the microenvironment in an anti-tumor manner. In the context of therapeutic targeting of SFKs, these results suggest that pan-SFK inhibitors may not produce the intended therapeutic benefit when Lyn is present.

AB - Src-family kinase (SFK) signaling impacts multiple tumor-related properties, particularly in the context of the brain tumor glioblastoma. Consequently, the pan-SFK inhibitor dasatinib has emerged as a therapeutic strategy, despite physiologic limitations to its effectiveness in the brain. We investigated the importance of individual SFKs (Src, Fyn, Yes, and Lyn) to glioma tumor biology by knocking down individual SFK expression both in culture (LN229, SF767, GBM8) and orthotopic xenograft (GBM8) contexts. We evaluated the effects of these knockdowns on tumor cell proliferation, migration, and motility-related signaling in culture, as well as overall survival in the orthotopic xenograft model. The four SFKs differed significantly in their importance to these properties. In culture, Src, Fyn, and Yes knockdown generally reduced growth and migration and altered motility-related phosphorylation patterns while Lyn knockdown did so to a lesser extent. However the details of these effects varied significantly depending on the cell line: in no case were conclusions about the role of a particular SFK applicable to all of the measures or all of the cell types examined. In the orthotopic xenograft model, mice implanted with non-target or Src or Fyn knockdown cells showed no differences in survival. In contrast, mice implanted with Yes knockdown cells had longer survival, associated with reduced tumor cell proliferation. Those implanted with Lyn knockdown cells had shorter survival, associated with higher overall tumor burden. Together, our results suggest that Yes signaling directly affects tumor cell biology in a pro-tumorigenic manner, while Lyn signaling affects interactions between tumor cells and the microenvironment in an anti-tumor manner. In the context of therapeutic targeting of SFKs, these results suggest that pan-SFK inhibitors may not produce the intended therapeutic benefit when Lyn is present.

KW - Dasatinib

KW - Glioblastoma

KW - Lyn kinase

KW - Migration

KW - Proliferation

KW - Src-family kinase

UR - http://www.scopus.com/inward/record.url?scp=84940857288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940857288&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2015.06.001

DO - 10.1016/j.molonc.2015.06.001

M3 - Article

C2 - 26105207

AN - SCOPUS:84940857288

VL - 9

SP - 1783

EP - 1798

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 9

ER -